Migren Baş Ağrısı Olan Katılımcılarda Galkanezumab (LY2951742) Çalışması

Sade dilde özet

Bu çalışma, migren baş ağrısı olan hastalarda Galkanezumab (LY2951742, bir CGRP antikoru) ilacını plaseboyla karşılaştırıyor. En az 1 yıldır migren öyküsü olan, migreni 50 yaşından önce başlamış hastalar dahil edilmiştir. Faz 2 aşamasında yürütülmüş ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

Faz 2 (Phase 2)

Durum

Tamamlandı

Sponsor

Eli Lilly and Company

Müdahale

Galcanezumab, Placebo

Başlangıç

07.07.2014

Tahmini bitiş

12.02.2018

Ülkeler

United States

İlgili genler

Merkezler

• Gilbert, United States
• Phoenix, United States
• Phoenix, United States
• Encino, United States
• Long Beach, United States
• Los Alamitos, United States
• Newport Beach, United States
• Rancho Mirage, United States
• San Diego, United States
• San Diego, United States
• San Francisco, United States
• Santa Monica, United States
• Boulder, United States
• Stamford, United States
• DeLand, United States
• Maitland, United States
• Ocala, United States
• Orlando, United States
• West Palm Beach, United States
• Edgewood, United States
• Baltimore, United States
• Boston, United States
• Ann Arbor, United States
• Kalamazoo, United States
• Springfield, United States
• St Louis, United States
• Albuquerque, United States
• Plainview, United States
• Rochester, United States
• Greensboro, United States
• Winston-Salem, United States
• Portland, United States
• Philadelphia, United States
• Mt. Pleasant, United States
• Memphis, United States
• Austin, United States
• Austin, United States
• Bellevue, United States
• Seattle, United States
• Middleton, United States

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

* Participants with a history of migraine of at least 1 year prior to enrollment.
* Migraine onset prior to age 50.

Exclusion Criteria:

* Current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device.
* Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).
* History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine, and basilar-type migraine.
* Have a history or presence of other medical illness that indicates a medical problem that would preclude study participation.
* Failure to respond to more than two adequately dosed effective migraine prevention treatments.
* Evidence of significant active psychiatric disease, in the opinion of the investigator.
* Women who are pregnant or nursing.